New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback